Companies › Biofabri
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MTBVAC Attenuated M. tuberculosis vaccine with deletions in phoP and fadD26 genes | – | Phase 3 | Tuberculosis | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04975178 | MTBVAC | Phase 3 | Tuberculosis | Infectious disease | Feb 2029 |
No annotated target.
–
Chengdu CoenBiotech Vedanta Biosciences Novavax Valneva Austria Osivax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.